Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Sanwa Kagaku Licenses FYX-051 from Fuji Yakuhin
October 19, 2009
- Korosho to Continue to Support Development of Unapproved Drugs via Non-budgetary Measures
October 19, 2009
- Meiji Seika Aims at Top-3 Position in CNS
October 19, 2009
- No More Problems with Speed or Quality of Clinical Trials in Japan: Korosho's WG
October 19, 2009
- Daiichi Sankyo to Make Vaccines One of Its Core Businesses
October 19, 2009
- R&D NEWS IN BRIEF
October 19, 2009
- New Drugs Account for 13% of Total Sales: Novartis
October 19, 2009
- Sandoz's Somatropin Equivalent to Original Product: Mr Nakamichi
October 19, 2009
- Sales Force Effectiveness Summit Japan 2009
October 19, 2009
- JSGM to Propose Standard Prescription Ordering Form
October 19, 2009
- BUSINESS NEWS IN BRIEF
October 19, 2009
- Pharmacists Should Play Key Role in Promoting Use of Generics: JSGM Seminar
October 19, 2009
- Discussions on Medical Fees Halted
October 19, 2009
- Korosho Urges Nat'l Univ. Hospitals to Use More Generics
October 19, 2009
- Industry Should Show Evidence of Pressure on Profits due to Drug Price Curtailment: JMARI
October 19, 2009
- 2012 IGPA Annual Conference to Be Held in Japan
October 19, 2009
- Budget to Support Development of Unapproved Drugs, Indications Cut to ¥10 Bil.
October 19, 2009
- HSTTC Licenses Tumor Markers to TransGenic
October 19, 2009
- Korosho's Supplementary Budget Cut by ¥435.9 Bil.
October 19, 2009
- TOPICS 2 articles
October 19, 2009
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…